Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. It offers nucleic acid and real-time PCR kits, as well as consumables. The company was founded in 2005 and is based in Shanghai, China.
Shanghai ZJ Bio-Tech Co. Ltd. A (688317) - Total Liabilities
Latest total liabilities as of September 2025: CN¥327.17 Million CNY
Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has total liabilities worth CN¥327.17 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai ZJ Bio-Tech Co. Ltd. A - Total Liabilities Trend (2013–2024)
This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Opple Lighting Co Ltd
SHG:603515
|
China | CN¥2.61 Billion |
|
International Personal Finance plc
PINK:IPFPF
|
USA | $724.20 Million |
|
E&R Engineering
TWO:8027
|
Taiwan | NT$1.49 Billion |
|
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
|
USA | $10.38 Million |
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
China | CN¥578.12 Million |
|
Dong Fang Offshore Co., Ltd.
TW:7786
|
Taiwan | NT$6.69 Billion |
|
Real Matters Inc
PINK:RLLMF
|
USA | $15.92 Million |
|
Rejlerkoncernen AB
F:3RE
|
Germany | €1.87 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai ZJ Bio-Tech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2024)
The table below shows the annual total liabilities of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥153.06 Million | -38.59% |
| 2023-12-31 | CN¥249.25 Million | -54.13% |
| 2022-12-31 | CN¥543.44 Million | +27.19% |
| 2021-12-31 | CN¥427.27 Million | +2.47% |
| 2020-12-31 | CN¥416.97 Million | +494.94% |
| 2019-12-31 | CN¥70.09 Million | +49.20% |
| 2018-12-31 | CN¥46.98 Million | +8.18% |
| 2017-12-31 | CN¥43.42 Million | +1.78% |
| 2016-12-31 | CN¥42.66 Million | -16.06% |
| 2015-12-31 | CN¥50.82 Million | -43.07% |
| 2014-12-31 | CN¥89.28 Million | +72.51% |
| 2013-12-31 | CN¥51.75 Million | -- |